Cetuximab in First Line Treatment of Metastatic Colorectal Cancer

Farmeconomia. Health economics and therapeutic pathways
doi 10.7175/fe.v13i1s.305
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Seed SRL

Related search

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Efficacy of Continued Cetuximab for Unresectable Metastatic Colorectal Cancer After Disease Progression During First-Line Cetuximab-Based Chemotherapy: A Retrospective Cohort Study

Oncotarget
Oncology
2016English

Metastatic Colorectal Cancer First-Line Treatment With Bevacizumab: The Impact of K-Ras Mutation

OncoTargets and Therapy
OncologyPharmacology
2013English

Reply: Capecitabine and Bevacizumab as First-Line Treatment in Elderly Patients With Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2010English

Xeloda as First-Line Therapy of Metastatic Colorectal Cancer-Our Experience

Archive of Oncology
OncologyHematology
2002English

First-Line Treatment of Metastatic Lung Cancer—New Developments

Oncology & Hematology Review (US)
2008English

PCN70 Cost-Effectiveness of Cetuximab and Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer (mCRC) for Patients With Kras Wild-Type Tumours in the United Kingdom

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-Line Cetuximab and Irinotecan

JAMA Oncology
Cancer ResearchOncology
2019English

Molecular Targeted Treatment of Metastatic Colorectal Cancer: The Cardiovascular Adverse Effects of Bevacizumab and Cetuximab

Medicine and Pharmacy Reports
Medicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy